Monopar Therapeutics Inc.
MNPR
$59.27
-$1.72-2.82%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 52.40% | -163.56% | -43.04% | -59.94% | -502.33% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -91.96% | 452.08% | 282.63% | 312.23% | 916.85% |
| Change in Net Operating Assets | -64.85% | 682.02% | 132.65% | -1,181.25% | 2,090.93% |
| Cash from Operations | -68.64% | -94.74% | 35.75% | -242.11% | -29.27% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -333.72% | -315.68% | 49,570.83% | 66.87% | -582.71% |
| Cash from Investing | -333.72% | -315.68% | 49,570.83% | 66.87% | -582.71% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | 4,600.00% | -99.52% | 16,435.39% |
| Repurchase of Common Stock | -475.04% | -214,333.33% | -3,116.00% | -1,125.23% | -1,162.26% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.69% | 560,049.09% | -3,100.00% | -103.64% | 16,682.30% |
| Foreign Exchange rate Adjustments | 2,718.42% | -91.11% | -273.33% | 94.12% | 54.76% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -265.45% | 88,452.10% | 87.59% | -1,227.41% | 2,173.16% |